LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

LEO Pharma has entered into an exclusive global license and transfer agreement with Boehringer Ingelheim for the commercialization and further development of SPEVIGO (spesolimab), a monoclonal antibody targeting the IL-36 receptor for generalized pustular psoriasis (GPP)124.

The deal gives LEO Pharma exclusive global rights to Spevigo in exchange for an upfront payment of €90 million ($105 million), along with possible additional milestone payments and royalties24.

Spesolimab is approved by the US FDA for the treatment of GPP in adults and adolescents aged 12 and above weighing at least 40 kg, and it is the first therapy specifically indicated for GPP flares4.

The partnership combines Boehringer Ingelheim’s immunology expertise and global reach with LEO Pharma’s six decades of specialized dermatology experience to broaden access to Spevigo and explore its use in other dermatological conditions involving IL-3612.

Transaction completion is expected in the second half of 2025, pending regulatory approval4.

Sources:

1. https://www.leo-pharma.com/media-center/news/2025-boehringer-ingelheim-and-leo-pharma-enter-partnership

2. https://www.pharmaceuticalcommerce.com/view/leo-pharma-commercialization-spevigo-105m-boehringer-ingelheim

4. https://www.dermatologytimes.com/view/boehringer-ingleheim-leo-pharma-announce-partnership-to-advance-spesolimab-in-gpp-and-beyond